Ozempic Lawsuit & Ozempic Class Action Lawyer

The judge overseeing the Ozempic MDL confirmed that evidence will be examined by the court. What will be examined is the strength of the evidence which links GLP-1 drugs like Ozempic and Wegovy to gastroparesis as well as other injuries like ileus. This will occur before case-specific discovery occurs or bellwether trials occur.

A case management order which was issued on October 25 confirmed that general causation will be addressed by the court during the initial discovery phase.

General causation involves evaluating if the plaintiffs possess sufficient evidence in order to establish that GLP-1 drugs can cause the injuries that the plaintiffs have experienced.

General causation will be examined regarding gallbladder injuries, small bowel obstruction, ileus and gastroparesis.

The judge also noted that the number of cases involving deep vein thrombosis is growing, but that these lawsuits have not been added to the MDL. The U.S. Judicial Panel on Multidistrict Litigation would need to make the decision to add them to the MDL. The judge indicated that if DVT injuries are added, the court will consider general causation regarding those injuries.

A lawsuit filed on October 10 in Pennsylvania by a Kansas man alleges that the man developed gastroparesis after using Ozempic. The lawsuit alleges the condition got confirmed via a test of gastric emptying.

According to the lawsuit, the man received an Ozempic prescription in 2022 for diabetes treatment. However, the man quickly started suffering from vomiting and abdominal pain.

Following persistent side effects, the man had a gastric emptying test done, and this revealed a diagnosis of gastroparesis.

The lawsuit alleges the man has suffered severe injuries which are possibly permanent, alleging these injuries may have been avoided had the manufacturer adequately warned of the risk of gastroparesis.

Over 1,000 lawsuits now pending in federal court allege that GLP-1 drugs like Ozempic have led to serious gastrointestinal side effects such as gastroparesis.

A lawsuit filed on September 26 in Pennsylvania by a Kentucky man alleges that the man developed ileus due to the side effects of Ozempic and Rybelsus. Ileus is a condition where intestinal muscles don't contract properly in order to move food throughout the digestive tract.

The lawsuit alleges that the man suffered from constipation, abdominal discomfort, vomiting and severe nausea which required multiple emergency room trips.

The lawsuit claims that Novo Nordisk knew for years that Rybelsus and Ozempic can cause ileus yet failed to warn the medical community and users about this risk.

A lawsuit was filed by an Alabama woman in Pennsylvania on September 13, alleging that Eli Lilly failed to warn that Mounjaro may cause patients to develop gastroparesis, also known as stomach paralysis.

The lawsuit alleges that the plaintiff used the medication between August 2022 and April 2023, developing gastroparesis which involved malnutrition, extreme constipation, constant nausea, and cyclical vomiting which was so bad that she needed to go to the ER.

GLP-1 medication manufacturers such as Eli Lilly are facing over 800 lawsuits in a multidistrict litigation.

Novo Nordisk is currently testing a Wegovy pill. The weight loss medication contains semaglutide, the active ingredient in the diabetes medication Ozempic.

The drug manufacturer has indicated that those who have received the pill have experienced significant body weight reduction after taking the pill for three years.

While drug makers claim that GLP-1 drugs like Ozempic and Wegovy are safe and effective, hundreds of lawsuits allege that the drugs have caused patients to develop serious gastrointestinal side effects such as gastroparesis, or stomach paralysis.

A lwsuit filed on September 5 by a Kentucky woman in Pennsylvania alleges that she developed stomach paralysis after taking Ozempic for only a few months.

The lawsuit is one of hundreds claiming that GLP-1 drugs like Ozempic, Wegovy and Mounjaro caused patients to develop gastroparesis.

The lawsuits allege that the manufacturers of the drugs put profits ahead of the safety of consumers by not properly warning the medical community and patients regarding the risk of gastroparesis associated with the drugs.

The lawsuit claims that the woman began using Ozempic in January of 2023 and had developed stomach paralysis by April of 2023, leading to severe abdominal pain and persistent vomiting. She alleges she required emergency treatment before being diagnosed with stomach paralysis.

The lawsuit alleges the woman has been left with serious, permanent injuries.

The judge presiding over the Ozempic MDL has indicated that prior to individual cases being prepared for trials, preemption motions will be first ruled on by the court, who will determine if plaintiffs need to have diagnostic testing done to establish their gastroparesis injuries.

Hundreds of lawsuits have been filed alleging that users of GLP-1 drugs such as Ozempic, Mounjaro and Wegovy have developed serious gastrointestinal issues such as gastroparesis, or stomach paralysis.

Since the drugs are so widely used, it is expected that the litigation may eventually involve tens of thousands of lawsuits.

The defendants in the litigation are arguing that gastroparesis can only be reliably diagnosed via objective testing. However, this testing is not typically ordered by doctors because treatment courses are not impacted by the testing.

In other news, the GLP-1 drug MDL grew by over 500 new cases in August. 869 cases are now pending in the MDL.

A lawsuit filed by a Florida woman in Pennsylvania on August 23 alleges she suffered painful injuries when Ozempic degraded her intestines' ability to move the contents of her stomach through her digestive tract, leading to intestinal obstruction, ileus and gastroparesis.

The lawsuit seeks financial compensation from Novo Nordisk for their failure to warn the public about risks associated with Ozempic.

The lawsuit alleges the woman suffered from constant vomiting and nausea, leading to emergency medical treatment.

The lawsuit is one of hundreds alleging that the GLP-1 RA drug caused severe gastrointestinal side effects which Novo Nordisk knew or should have known about but failed to warn about.

A new study found that patients taking Ozempic disproportionately experience suicidal thoughts. The researchers called for further studies on the subject.

The researchers found that users of Wegovy and Ozempic saw a 45 percent greater risk of suicidal thoughts than those not taking the drugs.

The researchers also discovered that the risk of thinking about suicide increased by more than four times when the drugs were taken with benzodiazepines and antidepressants simultaneously.

It was noted by the researchers that while Wegovy is required to carry a depression and suicide warning by the FDA, Ozempic is not.

Individual who use the medications Ozempic, Zepbound, Mounjaro or Wegovy prior to having digestive tract exams done might face a higher risk of suffering aspiration while the procedure is done, according to a new study.

The study involved searching for evidence that aspiration occurred in patients on GLP-1 RA drugs during esophagogastroduodenoscopy procedures. These procedures involve endoscopic examinations of upper gastrointestinal tracts during sedation.

The researchers examined data on almost 60,000 patients who took a GLP-1 RA drug before having the procedure done, as well as almost six million patients who didn't take a GLP-1 RA drug prior to the procedure.

A "significant risk" of experiencing aspiration pneumonitis was seen in patients who took drugs like Mounjaro and Ozempic.

Last year saw the initial alarm sounded by the American Society of Anesthesiologists regarding the risks of aspiration during sedation associated with the class of medications.

Multiple aspiration lawsuits have been filed by users of drugs such as Ozempic, alleging the drugs' manufacturers should have done a better job of warning doctors and users about how important it is to stop using the drugs prior to being sedated for procedures.

The judge overseeing the Ozempic MDL announced that next month will see a "Science Day" be held, following a hearing previously scheduled for June 2024 got canceled following the death of the original judge overseeing the MDL.

This hearing will let the plaintiffs and defendants provide the court with education regarding the science behind claims that diabetes and weight loss medications such as Ozempic, Zepbound, Mounjaro and Wegovy caused people to develop gastrointestinal problems such as gastroparesis, or stomach paralysis.

Users of the medication have filed over 100 lawsuits alleging that the drugs' users were inadequately warned regarding serious side effects which the injections may cause.

The lawsuits claim that drug manufacturers put profits over the safety and health of consumers when they minimized info regarding gastrointestinal problems' severity and the medications' long-term risks.

"Science Days" usually involve presentations by parties or expert witnesses, which are non-adversarial, intended to provide courts with education regarding concepts and issues which will be brought up during litigation. These presentations aren't subject to cross-examination or part of the cases' official records, but the info presented might guide courts in future motions or rulings regarding evidence which is presented in litigation, such as decisions regarding what testimony from expert witnesses might get presented before juries.

A lawsuit filed by a Pennsylvania man in Pennsylvania on August 5 alleges that he developed paralysis in his intestines' nerve endings after taking Trulicity, leading to an intestinal obstruction that left him with permanent and severe gastrointestinal injuries.

The lawsuit alleges that Eli Lilly & Company did not adequately research the drug's side effects or warn regarding complications that its users might experience.

The lawsuit alleges the man's intestinal obstruction caused him to end up experiencing diarrhea, nausea and abdominal pain which led to a hospitalization.

Trulicity is a GLP-1 RA drug, a class of drugs which also includes the medications Zepbound, Wegovy, Mounjaro and Ozempic. Thousands of lawsuits now allege that users of these drugs experienced serious gastrointestinal issues or vision issues due to use of the drugs.

According to an NBC News report, concerns are growing that using weight loss medications such as Zepbound or Wegovy may worsen or trigger eating disorders.

The drugs are known as GLP-1 RA medications and have become very popular for treating obesity. They have been linked with numerous health risks, such as gastroparesis (stomach paralysis) and vision problems. However, the report indicates that doctors are also raising alarms regarding increasing reports of eating disorders such as anorexia which may be due to dietary restrictions which are part of treatment regimens.

Experts cited in the report said that the brains of some people might interpret weight loss and reduced caloric intake as starvation, and users who are compelled to not eat as much might end up spiraling into habits which are unhealthy.

While concerns over side effects from GLP-1 RA drugs such as Ozempic are mounting, a doctor has warned emergency rooms to be prepared to give treatment to patients who are using the medications.

A doctor at Stanford Health Care, in a letter to the editor of the Annals of Emergency Medicine, has raised concerns regarding gastroparesis, also known as stomach paralysis, in patients who are taking the medications.

The doctor has warned that gastroparesis can increase the risk of vomiting or aspiration in patients who receive sedation prior to surgery. The doctor warned that if doctors aren't aware patients are taking Ozempic or similar drugs prior to surgery, they might not be prepared for aspiration occurring during surgery, which could cause patients to suffocate.

Aspiration can happen when patients inhale their own stomach's contents while sedated during surgery.

The doctor noted that while five percent of patients who fast prior to endoscopy have food in their stomach, that number rises to 25 percent in patients taking Wegovy or Ozempic.

The doctor suggests that intubation risks can be mitigated via the elevation of the heads of patients, decreasing oxygenation via bag-valve-masks, and ensuring the most skilled air operators are present.

The doctor also called on healthcare providers to talk about aspiration risks with patients, and to document this discussion for the purposes of legal protection.

Only around 25 percent of patients who are prescribed Wegovy or Ozempic stay on the medications for over two years, according to an investigation which was recently published. This suggest that many people who receive the diabetes and weight loss injections might end up quitting due to reasons including adverse health effects.

Many pending lawsuits now allege that individuals who have used the drugs have ended up with gastrointestinal side effects such as gastroparesis (stomach paralysis) and bowel obstructions.

According to the investigation, 24.1 percent of users of Wegovy kept taking the medication after two years, and 22.2 percent of Ozempic users kept taking the drug after two years.

In other news, a lawsuit filed in Pennsylvania on July 15 by a West Virginia man alleges that his gastroparesis injury may not have occurred had Novo Nordisk adequately warned that gastrointestinal issues could be a sign that stomach paralysis has occurred.

The lawsuit claims the company intentionally downplayed the risk of gastroparesis associated with Ozempic when dealing with the FDA and regarding the drug's warning label, for the purpose of increasing profits.

The lawsuit alleges the man experienced serious gastrointestinal issues like diarrhea, vomiting and nausea, leading to a gastroparesis diagnosis.

The judge overseeing pretrial management of the GLP-1 drug MDL, which involves drugs such as Ozempic and Wegovy, approved a process which is streamlined to allow families to file new claims directly against manufacturers of the weight loss and diabetes medications which have seen links made to reports of bowel obstruction, stomach paralysis and additional injuries.

A case management order was issued on July 14 in order to assist in avoiding delays which are associated with moving new lawsuits into the MDL.

It is common, in complex mass tort lawsuits involving large numbers of plaintiffs pursuing similar allegations and claims, for courts to approve master and short form complaints which allow plaintiffs to file lawsuits in the future via a process which is abbreviated, with all plaintiffs adopting identical relevant allegations. This process leads to easy sorting, filing and cataloging of large numbers of complaints. These complaints can then be utilized in order to figure out what claims might be test cases regarding early trials. The early trials, known as bellwether trials, let parties gauge how juries and courts will probably respond to certain testimony and evidence which will probably get repeated throughout litigation.

In other news, a lawsuit has been filed by an Illinois man against Eli Lilly and Novo Nordisk which claims that the companies failed to warn regarding the risks of the drugs Mounjaro and Ozempic.

The plaintiff received an Ozempic prescription in October 2022 for management of diabetes, and kept using the drug until January 2023, then switching to Mounjaro, which was also prescribed for the same reason.

In June 2023, the plaintiff went to the hospital with discomfort in his chest which later became severe abdominal pain. Bowel obstruction and ischemia were suggested by a CT scan, and the plaintiff needed surgery the next day.

The lawsuit seeks compensation for pain, suffering, medical expenses and injuries, which he claims were caused by the deceptive practices and negligence of the defendants.

A study published in JAMA Internal Medicine this past week found that weight loss and diabetes drugs using the active ingredient tirzepatide, including Zepbound and Mounjaro, might lead to a significantly higher amount of lost weight, than drugs using semaglutide, including Wegovy and Ozempic.

The medications are known as GLP-1 RAs and function by promoting the feeling of fullness and delaying gastric emptying. However, many lawsuits are now alleging that the drugs, by delaying gastric emptying, can cause gastroparesis, or stomach paralysis.

The study involved dosages involved in the treatment of diabetes, not dosages which are used for weight loss.

The study involved the data of 18,386 obese or overweight patients who were given either Mounjaro or Ozempic. The researchers found that patients taking Mounjaro were 76 percent more likely to achieve 5 percent or more weight loss within a year of treatment than patients taking Ozempic.

The study also found that patients receiving Mounjaro saw more weight loss at the three-month, six-month and 12-month marks.

The researchers noted high discontinuation rates among patients taking both medications, often because of gastrointestinal problems.

The researchers found that Ozempic was associated with 4.81 incidents of gastroparesis per 1,000 person-years, while Mounjaro was associated with 3.61 incidents of gastroparesis per 1,000 person years.

The researchers also noted that additional side effects of the drugs included bowel obstruction, pancreatitis, gall stones and gallbladder inflammation.

Four lawsuits were added to the Ozempic MDL in June, raising the total number of cases to 105.

A new lawsuit was filed on July 1 involving an Indiana woman who started taking Ozempic in the month of March 2022 for weight management and diabetes control. In July 2022, the woman went to an ER with vomiting, rectal bleeding and severe constipation, where she was diagnosed with a bowel obstruction after receiving an ultrasound.

The lawsuit alleges the woman continues to have irregular bowel movements, and that Ozempic's label failed to warn her or her doctor about the drug's true risks. The woman claims she has suffered a profound alteration to her life due to Ozempic.

A new study has found that GLP-1 RAs like Ozempic, Mounjaro and Wegovy can lead to a bone density loss.

The researchers analyzed a randomized clinical trial involving 195 obese adults and found that patients who were given the GLP-1 diabetes medication liraglutide experienced decreased bone mineral density in the spine and hips.

The researchers found that a combination of liraglutide and exercise preserved bone health, highlighting the importance of exercise when taking GLP-1 drugs.

A proposed class action lawsuit was filed in Canada, accusing Novo Nordisk of failing to warn prospective patients regarding possible complications.

Multiple patients have claimed that they experienced serious complications while they took Ozempic for weight loss or diabetes, believing they weren't warned about the complications.

Patients are claiming they've experienced gall bladder issues as well as severe gastrointestinal issues such as gastroparesis, or stomach paralysis, where food stays in the digestive system where it's delayed from voiding, causing severe pain in the stomach.

A lawsuit filed in Texas on June 4 alleges that a man required hospitalization numerous times after using the drug Ozempic for a period of about ten months, alleging the medication caused him to experience severe abdominal pain, extreme vomiting and additional events which have left the man with permanent injuries.

The lawsuit alleges the man started using the drug in January 2023, continuing to inject it until the month of October 2023. Because of the injections of Ozempic, the lawsuit alleges, the man developed severe digestive and gastrointestinal events, including severe abdominal pain and extreme vomiting, which the man claims weren't properly disclosed to the medical community or users.

The lawsuit accuses Novo Nordisk of downplaying the severity of digestive events and gastrointestinal events that Ozempic can cause, never warning about the risks of gastroparesis, gastroenteritis, or the need for gallbladder removal surgery.

A 2023 study found that the use of GLP-1 receptor agonist drugs such as Ozempic increases the risk of gastroparesis, or stomach paralysis, by three times compared to weight loss drugs which are not injected.

A federal panel of judges has ended up reassigning all GLP-RA weight loss and diabetes drug lawsuits, including lawsuits involving Ozempic, Wegovy and Mounjaro, to a new United States District Judge. The reassignment is occurring after the judge who was originally assigned to oversee the multidistrict litigation died.

Judge Gene Pratter was assigned to oversee the Ozempic MDL in February 2024. However, Pratter died on May 17 at age 75 because of COPD complications.

Judge Karen Marston was assigned to oversee the MDL on June 6 after a pause of almost one month in the MDL.

As Ozempic’s popularity continues to grow, as well as the popularity of other GLP-1 drugs like Mounjaro and Wegovy, concerns over the drugs’ side effects also continue to grow. A new study says these side effects include psychological changes which might affect skills related to decision making, increasing the risk that the drugs’ users engage in behaviors which are risky.

U.K. researchers say GLP-1 agonists might cause disorders relating to impulse control which may cause poor, sudden life choices, possibly resulting in addictive behaviors and sudden divorces.

The researchers are warning doctors that the drugs could cause problems like reckless life changes or addiction to sex or gambling.

The researchers note that some individuals, within a few months of starting treatment with the drugs, have made major changes to their lives such as divorces or house moves.

The researchers theorize that the drugs could lead to cognitive changes regarding decision making due to metabolic changes caused by weight loss as well as a direct effect of the drugs upon brain function.

In other news, 12 cases were added to the Ozempic MDL in May, bringing the total number of cases to 101.

While the number of lawsuits over GLP-1 RA drugs such as Ozempic, Wegovy and Mounjaro grows, the judge recently picked to preside over the MDL, which involves claims that the drugs cause stomach paralysis, has suddenly passed.

Gene E.K. Pratter, a U.S. District Judge, died on May 17 due to COPD complications. The judge was 75 and had served since 2004 in the United States District Court for the Eastern District of Pennsylvania.

Coordinated pretrial proceedings had just started, so it isn't likely that the reassignment of a new judge to preside over the Ozempic MDL will substantially delay the litigation. The judge had been expected to establish bellwether trials, but an order hadn't yet been issued outlining the timing or criteria for making bellwether trial selections.

Once a new judge is selected to preside over the MDL, the parties will likely wish to meet with the new judge in order to bring the judge up to speed regarding the litigation by having a status conference. Following this, the new judge will probably continue the bellwether program that Judge Pratter started by working with both parties to determine which lawsuits are the most representative of the overall litigation, then sending trials through discovery before scheduling bellwether trials.

After discovery and bellwether trials, if settlements or a different resolution aren't able to be reached, the new judge may remand claims back to the district courts they were originally filed in.

Novo Nordisk is facing a lawsuit filed by a New York woman who claims the drug manufacturer did not adequately warn doctors and users that Wegovy can cause gastroparesis, alleging that side effects of the medication caused her to require surgery in order to empty her stomach's contents.

The lawsuit, filed on April 23 in New York, seeks compensation based on the causes of action of deceptive and unfair marketing practices, defective design, failure to warn and negligence.

The lawsuit alleges that after each Wegovy injection, the plaintiffs experienced upper abdominal pain, bloating and vomiting. The lawsuit claims that the woman stopped using Wegovy in August 2023, yet continued to have severe side effects, eventually culminating in a diagnosis of food bolus in December and a diagnosis of severe gastroparesis in January 2024.

A "science day" will be held on June 14 during which parties in the Ozempic MDL will explain to the court the science behind claims alleging that GLP-1 RA drugs such as Ozempic, Trulicity, Zepbound, Mounjaro and Wegovy caused claimants to develop severe gastrointestinal injuries such as gastroparesis, intestinal obstructions and ileus.

Expert witnesses for each party will make presentations about the relevant products as well as any science which is relevant to lawsuits in the MDL.

Proceedings such as these usually involve presentations by parties or expert witnesses which are non-adversarial and intended to provide education to the court regarding concepts and issues which will be discussed during proceedings. While these presentations are not subject to cross examination and are not part of the case's official records, the info provided in the presentations can guide the court regarding future motions or rulings regarding evidence presented in the litigation, such as decisions regarding if expert witness testimony should be allowed or not.

Topics discussed will include the background of diseases which the drugs treat, background on the drugs, how the drugs work, the approved indications of the drugs, and the drugs' regulatory and labeling history. Additional topics discussed will include background on injuries involved in the litigation, including gastroparesis, intestinal obstruction, ileus, gallstones, gallbladder disease, deep vein thrombosis, and malnutrition, and medical literature related to the drugs and any alleged injuries.

A lawsuit has been filed in Kentucky by a Kentucky woman who alleges that she developed gastroparesis and bowel obstructions after receiving Wegovy injections.

The lawsuit claims that Novo Nordisk, the drug's manufacturer, did not adequately warn her about the risks of developing stomach paralysis and bowel obstructions associated with the drug, leading to her developing permanent health issues and serious injuries.

The lawsuit alleges that within seven months of being prescribed Wegovy, the woman had to go to the emergency room with vomiting, nausea and severe abdominal pain. The lawsuit alleges she eventually required numerous multi-day hospitalizations due to gastroparesis and bowel obstruction, and that the woman needs additional follow-up care.

In other news, 14 cases were added to the Ozempic MDL in April, bringing the total number of cases to 87.

A lawsuit was filed on April 17 in Iowa by an Iowa man who alleges that he developed gastroparesis as well as necrotizing pancreatitis after using Ozempic. The lawsuit alleges that the makers of Ozempic knew or should have known about the risks associated with the medication but did not adequately warn him about the risks associated with the drug.

The lawsuit claims that the man was given Ozempic from October 2021 to May 2022, and that he developed necrotizing pancreatitis and gastroparesis, causing him severe abdominal pain, vomiting, nausea, distributive shock, tachycardia and shortness of breath.

In other news, a new research letter has linked GLP-1 RA drugs like Ozempic with an increased risk of aspiration pneumonia during endoscopic procedures. The Cedars-Sinai Hospital researchers warn patients taking drugs such as Wegovy or Ozempic to stop using the medications before having endocopic procedures due to this risk.

Aspiration pneumonia happens when liquids or food enter the airways or lungs, causing lung infections. The condition has a 11 to 30 percent fatality rate.

The study involved almost 1 million United States patients who had endoscopy procedures, in which a tube-like device is inserted into the patient's throat in order to look at the body's insides.

The study found that the use of drugs like Ozempic can cause the stomach to retain food, leading to vomiting and nausea. If food is not cleared from the stomach prior to an endoscopic procedure, the food could lead to aspiration pneumonia, especially since patients are given anesthesia prior to these procedures.

The study found that a 0.8 percent risk of developing aspiration pneumonia exists for patients using GLP-1 RA drugs, and that this risk can be reduced by one-third when patients cease taking the drugs before the procedures.

The findings of the study come after a warning issued in 2023, which warned that GLP-1 drugs should not be taken prior to anesthesia due to a risk of food aspiration.

A plaintiffs' position statement submitted on April 9 in the Ozempic MDL claims that the labels of GLP1-RA drugs such as Ozempic do not adequately warn doctors and consumers about the risks associated with the drugs.

The statement claims that defendants in the litigation did not adequately warn doctors and consumers that the drugs may cause conditions like gastroparesis, bowel or intestinal obstruction, ileus, and secondary conditions associated with these conditions, like malnutrition.

The statement claims that the drugs' labels never warned adequately regarding the drugs' ability to impair food digestion, or that the drugs may cause relentless vomiting which requires hospitalization.

The statement claims that, rather than warning about a risk that gastroparesis, or stomach paralysis, may occur when taking the drugs, the labels instead downplay gastroparesis symptoms' severity, omitting that they can possibly cause digestive impairment which is life-threatening.

The statement also notes that the defendants in the litigation failed to advise users and prescribers of the drugs that users will probably have to take the drugs forever, or they'll just gain back the weight they lost when they took the drug, that much of the weight loss ends up being muscle loss, that gained weight after discontinuing the medication would end up being fat, and that because of the changed proportion of fat to muscle, patients would be worse off metabolically than before they took the drugs.

According to a new report by The Daily Mail, weight loss medications such as Ozempic have been linked with over 100 United States deaths.

The report states that the FDA has received 117 reports of incidents involving deaths regarding those taking GLP-1 RA drugs such as Ozempic, Mounjaro and Wegovy. Included in the reports was a pregnant woman and a 28-year-old woman who ended up developing an intestinal mass.

81 of the reports were linked with semaglutide, Ozempic's active ingredient.

The FDA has also received reports of pancreatic cancer and seizures.

In other news, a woman filed a lawsuit in Iowa in April 5 alleging that she has suffered permanent, severe injuries after using the GLP-RA drug Trulicity. The woman alleges she has suffered extreme abdominal pain, diarrhea and persistent vomiting, and has had to visit the emergency room numerous times.

The lawsuit alleges she has developed permanent stomach paralysis, alleging that Eli Lilly knew or should have known that Trulicity could cause gastroparesis but failed to warn about this risk.

A lawsuit filed in Pennsylvania by a Texas woman on March 26 alleges the woman needed a gallbladder removal and suffered additional serious gastrointestinal issues after taking Ozempic, which was prescribed to her by doctor for weight loss.

The lawsuit alleges Novo Nordisk didn't provide sufficient warnings regarding the serious nature of side effects associated with Ozempic.

The lawsuit claims the woman developed vomiting and severe nausea after taking Ozempic, and was diagnosed with gastritis, which she was eventually hospitalized for. When she was hospitalized, the lawsuit claims she was diagnosed with uncontrolled vomiting and a hiatial hernia.

Several months later, the lawsuit claims, the woman needed a gallbladder removal after being diagnosed with inflammation of her gallbladder.

There were 74 cases pending in the Ozempic MDL on April 1, 2024.

A hearing was held on March 13 in the Ozempic MDL. The hearing was regarding how cases should end up proceedings.

Dozens of plaintiffs are claiming that they didn't receive any warnings about possible dangers associated with Ozempic.

It is believed 10,000 or more cases could end up being filed in the MDL.

The MDL is being handled in Philadelphia, Pennsylvania because it's close to the headquarters of Novo Nordisk, which is located in New Jersey.

A lawsuit filed in Pennsylvania alleges that a Pennsylvania woman developed gastroparesis after taking Ozempic and Trulicity. The lawsuit alleges the woman suffered painful, severe injuries, including severe nausea and bowel obstruction. The lawsuit claims the woman required multiple visits to the emergency room due to the gastroparesis. The lawsuit alleges that the manufacturer of the drugs, Novo Nordisk, knew that the drugs could cause gastroparesis for many years but failed to adequately warn healthcare providers and patients.

A New York woman has filed a lawsuit against Eli Lilly, alleging that she developed severe sepsis, intestinal obstructions and additional complications, necessitating multiple surgeries and leaving her with permanent injuries, as a result of taking Mounjaro. The lawsuit alleges that Eli Lilly failed to adequately warn the medical community or users that Mounjaro might cause gastroparesis, or stomach paralysis. The lawsuit alleges the plaintiff suffered adhesions to the small intestines, a high-grade large bowel obstruction, severe sepsis and toxic megacolon, resulting in the necessity of emergency resection of her small and large intestines, in addition to a complete colectomy and the need for a colostomy bag.

United States District Judge Gene E.K. Pratter, on February 15, issued a case management order which called for an initial status conference in the Ozempic MDL to be held on March 14. The judge indicated that the focus of the conference will be regarding how the MDL is conducted. The conference will cover the process of selecting lead counsel, the frequency and format of status conferences, how new filings are managed, a schedule regarding expected filings, and procedures for filings of motions.

An Illinois woman has filed a lawsuit against Novo Nordisk alleging that Ozempic caused her to experience a blocked bowel as well as extreme vomiting and pain. The lawsuit alleges the woman's vomiting was so severe that she suffered a torn esophagus from it, requiring a week spent in the hospital.

The lawsuit is part of a batch of almost 60 lawsuits filed against the company, lawsuits which include allegations that a woman will have diarrhea for the rest of her life because of the drug, that a man required partial intestine removal due to the drug, and that a woman required gallbladder removal surgery due to the drug.

A determination has been made by the U.S. Judicial Panel for Multidistrict Litigation (JPML): all stomach paralysis lawsuits involving GLP-1 receptor agonist drugs, such as Ozempic, Mounjaro, Wegovy, Rybelsus and Trulicity, will be consolidated in front of a single federal judge in Pennsylvania for a multidistrict litigation (MDL). U.S. District Judge Gene E.K. Pratter will oversee the MDL.

There are currently 18 GLP-1 receptor agonist lawsuits in federal court, but it is anticipated that hundreds or thousands of similar lawsuits will be filed in the future. The JPML noted that it has been estimated that almost 2 percent of the United States population has been prescribed a GLP-1 receptor agonist drug.

The lawsuits allege that the drugs can cause gastroparesis, or stomach paralysis, that their manufacturers knew or should have known about this risk, and that their manufacturers failed to warn about this risk.

Reuters has reported that it is suspected that three United States cases of hypoglycemia, or blood sugar which is dangerously low, were caused by fake Ozempic.

According to America's Poison Centers, another person developed hypoglycemia after they injected a compounded version of the drug.

Last year, health authorities and Lebanon and Austria reported that many people developed hypoglycemia after they took Ozempic which was suspected to be fake - some of them were hospitalized.

A health regulator in Austria said those products probably contained insulin rather than semaglutide, the active ingredient in Ozempic. A drug regulator in Belgium confirmed that fake Ozempic which was seized in Belgium contained insulin.

A federal judge has ruled that Novo Nordisk is subject to an injury lawsuit in Louisiana filed by a Louisiana woman regarding Ozempic. The judge ruled that the company’s connections to the state and linked closely enough to the claims of the plaintiff to support Louisiana jurisdiction. The woman alleges that Ozempic caused her to suffer from severe bouts of vomiting which caused her to lose teeth. The court ruled that Louisiana jurisdiction is supported by the company’s purposeful and voluntary contacts with the state. The court ruled that Novo Nordisk developed the drug, placing it into the marketplace expecting it to be sold in every state, including Louisiana.

Novo Nordisk, in addition to plaintiffs, has asked a federal judge's panel to centralize and consolidate Ozempic and Wegovy stomach paralysis lawsuits before a single judge in a multidistrict litigation for pretrial proceedings and coordinated discovery. Over 40 complaints have been filed in federal court against the company and the makers of similar drugs, alleging that the GLP-1 receptor agonist drugs can cause side effects which were not warned about, such as gastroparesis. It is believed that thousands of claims are currently being investigated.

The FDA has indicated that an investigation has been launched into possible increased risks of adverse side effects connected with Ozempic, Mounjaro, Wegovy and similar drugs, including suicide and hair loss. A recent quarterly report linked GLP-1 receptor agonist drugs to aspiration, alopecia, suicidal ideation and suicide.

A lawsuit filed in Louisiana alleges that a woman suffered from gastroparesis, severe vomiting and diarrhea after using Ozempic. The woman allegedly needed multiple visits to the emergency room and required medication. The lawsuit alleges that the woman has been left with permanent, severe stomach paralysis which will require medical monitoring in the future. The lawsuit claims Novo Nordisk knew about or should have known about the risk of gastroparesis associated with Ozempic but failed to warn about it.

Plaintiffs have asked United States judges to form a federal multidistrict litigation covering a growing number of lawsuits regarding gastroparesis (stomach paralysis) being caused by GLP-1 receptor agonist drugs such as Ozempic, Mounjaro and Wegovy. According to the plaintiffs' motion, while there are 18 cases currently pending in courts, attorneys are currently performing investigations into over 10,000 claims which might be filed in the future.

The FDA has changed Ozempic's label to warn about the risk of ileus, which is when intestines can't normally contract to move waste through and out of the body.